Phase II trial of echinomycin in patients with advanced or recurrent colorectal cancer

Scott Wadler, Laura Tenteromano, Lorraine Cazenave, Joseph A. Sparano, Edward S. Greenwald, Alla Rozenblit, Ronald Kaleya, Peter H. Wiernik

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Echinomycin is a novel bifunctional intercalating agent derived from Streptomyces echinatus. A phase II clinical trial of echinomycin in patients with advanced, measurable colorectal cancer was initiated to determine the efficacy and toxicities of this agent. Echinomycin, 1.5 mg/m2, was given initially as a 30-to 60-min infusion every 4 weeks. After 4 episodes of anaphylaxis had occurred among the first 14 patients, the schedule was changed to a 24-h infusion, and an additional 16 patients were treated on this schedule. Treatment was given every 3 weeks. A total of 30 patients were eligible and evaluable; there were 3 (10%; 90% confidence interval, 3%-23%) clinical responses lasting 3, 3+, and 12 months, respectively. The most serious toxicity encountered was anaphylaxis, which occurred in 5 patients, although with no serious sequelae. A premedication regimen with dexamethasone, diphenhydramine, and cimetidine and a change in the duration of the infusion to 24 h reduced the incidence of this complication. Grade 2-3 vomiting occurred among earlier patients treated; however, with the 21-h schedule this toxicity was substantially reduced. The sole important case of hematologic toxicity was a single patient with grade 3 thrombocytopenia. Echinomycin employed in this dose and schedule had modest activity against colorectal cancer, comparable with that observed with 5-fluorouracil. Further studies in patients with gastrointestinal malignancies using a 24-h infusion with a dexamethasone premedication regimen similar to that employed prior to administration of taxol may be warranted.

Original languageEnglish (US)
Pages (from-to)266-269
Number of pages4
JournalCancer Chemotherapy and Pharmacology
Volume34
Issue number3
DOIs
StatePublished - May 1994

Fingerprint

Echinomycin
Toxicity
Colorectal Neoplasms
Appointments and Schedules
Dexamethasone
Intercalating Agents
Premedication
Diphenhydramine
Anaphylaxis
Cimetidine
Paclitaxel
Fluorouracil
Phase II Clinical Trials
Streptomyces
Vomiting
Confidence Intervals

Keywords

  • Colorectal cancer
  • Echinomycin
  • Phase II

ASJC Scopus subject areas

  • Pharmacology
  • Oncology
  • Cancer Research

Cite this

Phase II trial of echinomycin in patients with advanced or recurrent colorectal cancer. / Wadler, Scott; Tenteromano, Laura; Cazenave, Lorraine; Sparano, Joseph A.; Greenwald, Edward S.; Rozenblit, Alla; Kaleya, Ronald; Wiernik, Peter H.

In: Cancer Chemotherapy and Pharmacology, Vol. 34, No. 3, 05.1994, p. 266-269.

Research output: Contribution to journalArticle

Wadler, Scott ; Tenteromano, Laura ; Cazenave, Lorraine ; Sparano, Joseph A. ; Greenwald, Edward S. ; Rozenblit, Alla ; Kaleya, Ronald ; Wiernik, Peter H. / Phase II trial of echinomycin in patients with advanced or recurrent colorectal cancer. In: Cancer Chemotherapy and Pharmacology. 1994 ; Vol. 34, No. 3. pp. 266-269.
@article{a8415c7b79eb4555b1811500b13ccb24,
title = "Phase II trial of echinomycin in patients with advanced or recurrent colorectal cancer",
abstract = "Echinomycin is a novel bifunctional intercalating agent derived from Streptomyces echinatus. A phase II clinical trial of echinomycin in patients with advanced, measurable colorectal cancer was initiated to determine the efficacy and toxicities of this agent. Echinomycin, 1.5 mg/m2, was given initially as a 30-to 60-min infusion every 4 weeks. After 4 episodes of anaphylaxis had occurred among the first 14 patients, the schedule was changed to a 24-h infusion, and an additional 16 patients were treated on this schedule. Treatment was given every 3 weeks. A total of 30 patients were eligible and evaluable; there were 3 (10{\%}; 90{\%} confidence interval, 3{\%}-23{\%}) clinical responses lasting 3, 3+, and 12 months, respectively. The most serious toxicity encountered was anaphylaxis, which occurred in 5 patients, although with no serious sequelae. A premedication regimen with dexamethasone, diphenhydramine, and cimetidine and a change in the duration of the infusion to 24 h reduced the incidence of this complication. Grade 2-3 vomiting occurred among earlier patients treated; however, with the 21-h schedule this toxicity was substantially reduced. The sole important case of hematologic toxicity was a single patient with grade 3 thrombocytopenia. Echinomycin employed in this dose and schedule had modest activity against colorectal cancer, comparable with that observed with 5-fluorouracil. Further studies in patients with gastrointestinal malignancies using a 24-h infusion with a dexamethasone premedication regimen similar to that employed prior to administration of taxol may be warranted.",
keywords = "Colorectal cancer, Echinomycin, Phase II",
author = "Scott Wadler and Laura Tenteromano and Lorraine Cazenave and Sparano, {Joseph A.} and Greenwald, {Edward S.} and Alla Rozenblit and Ronald Kaleya and Wiernik, {Peter H.}",
year = "1994",
month = "5",
doi = "10.1007/BF00685088",
language = "English (US)",
volume = "34",
pages = "266--269",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Phase II trial of echinomycin in patients with advanced or recurrent colorectal cancer

AU - Wadler, Scott

AU - Tenteromano, Laura

AU - Cazenave, Lorraine

AU - Sparano, Joseph A.

AU - Greenwald, Edward S.

AU - Rozenblit, Alla

AU - Kaleya, Ronald

AU - Wiernik, Peter H.

PY - 1994/5

Y1 - 1994/5

N2 - Echinomycin is a novel bifunctional intercalating agent derived from Streptomyces echinatus. A phase II clinical trial of echinomycin in patients with advanced, measurable colorectal cancer was initiated to determine the efficacy and toxicities of this agent. Echinomycin, 1.5 mg/m2, was given initially as a 30-to 60-min infusion every 4 weeks. After 4 episodes of anaphylaxis had occurred among the first 14 patients, the schedule was changed to a 24-h infusion, and an additional 16 patients were treated on this schedule. Treatment was given every 3 weeks. A total of 30 patients were eligible and evaluable; there were 3 (10%; 90% confidence interval, 3%-23%) clinical responses lasting 3, 3+, and 12 months, respectively. The most serious toxicity encountered was anaphylaxis, which occurred in 5 patients, although with no serious sequelae. A premedication regimen with dexamethasone, diphenhydramine, and cimetidine and a change in the duration of the infusion to 24 h reduced the incidence of this complication. Grade 2-3 vomiting occurred among earlier patients treated; however, with the 21-h schedule this toxicity was substantially reduced. The sole important case of hematologic toxicity was a single patient with grade 3 thrombocytopenia. Echinomycin employed in this dose and schedule had modest activity against colorectal cancer, comparable with that observed with 5-fluorouracil. Further studies in patients with gastrointestinal malignancies using a 24-h infusion with a dexamethasone premedication regimen similar to that employed prior to administration of taxol may be warranted.

AB - Echinomycin is a novel bifunctional intercalating agent derived from Streptomyces echinatus. A phase II clinical trial of echinomycin in patients with advanced, measurable colorectal cancer was initiated to determine the efficacy and toxicities of this agent. Echinomycin, 1.5 mg/m2, was given initially as a 30-to 60-min infusion every 4 weeks. After 4 episodes of anaphylaxis had occurred among the first 14 patients, the schedule was changed to a 24-h infusion, and an additional 16 patients were treated on this schedule. Treatment was given every 3 weeks. A total of 30 patients were eligible and evaluable; there were 3 (10%; 90% confidence interval, 3%-23%) clinical responses lasting 3, 3+, and 12 months, respectively. The most serious toxicity encountered was anaphylaxis, which occurred in 5 patients, although with no serious sequelae. A premedication regimen with dexamethasone, diphenhydramine, and cimetidine and a change in the duration of the infusion to 24 h reduced the incidence of this complication. Grade 2-3 vomiting occurred among earlier patients treated; however, with the 21-h schedule this toxicity was substantially reduced. The sole important case of hematologic toxicity was a single patient with grade 3 thrombocytopenia. Echinomycin employed in this dose and schedule had modest activity against colorectal cancer, comparable with that observed with 5-fluorouracil. Further studies in patients with gastrointestinal malignancies using a 24-h infusion with a dexamethasone premedication regimen similar to that employed prior to administration of taxol may be warranted.

KW - Colorectal cancer

KW - Echinomycin

KW - Phase II

UR - http://www.scopus.com/inward/record.url?scp=0028341460&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028341460&partnerID=8YFLogxK

U2 - 10.1007/BF00685088

DO - 10.1007/BF00685088

M3 - Article

C2 - 8004762

AN - SCOPUS:0028341460

VL - 34

SP - 266

EP - 269

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 3

ER -